产品
编 号：F753744
分子式：C22H30N8O2
分子量：438.53
分子式：C22H30N8O2
分子量：438.53
产品类型
规格
价格
是否有货
结构图
CAS No: 2562386-85-8
产品详情
生物活性：
HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC).
体外研究：
HDAC-IN-46 (compound 12c) has antiproliferative activity against MDA-MB-231, A549 and MCF-7 with IC50s of 88.46±10.5 μM, 83.34 ± 15.5 μM and 21.4±3.7 μM, respectively.HDAC-IN-46 (5, 12.5 and 25 μM; 24 h) causes concentration-dependent upregulation of p-p38 and downregulation of Bcl-xL and cyclin D1 in MDA-MB-231 cells.HDAC-IN-46 (12.5 and 25 μM; 48 h) induces significant G2 phase arrest and apoptosis.
HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC).
体外研究：
HDAC-IN-46 (compound 12c) has antiproliferative activity against MDA-MB-231, A549 and MCF-7 with IC50s of 88.46±10.5 μM, 83.34 ± 15.5 μM and 21.4±3.7 μM, respectively.HDAC-IN-46 (5, 12.5 and 25 μM; 24 h) causes concentration-dependent upregulation of p-p38 and downregulation of Bcl-xL and cyclin D1 in MDA-MB-231 cells.HDAC-IN-46 (12.5 and 25 μM; 48 h) induces significant G2 phase arrest and apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备